Biogen Stock Analysis


USD 267.00  2.72  1.03%   

The current price rise of Biogen Inc could raise concerns from investors as the firm is trading at a share price of 267.00 on 3,748,016 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.38. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biogen partners.
Continue to Trending Equities.
The Biogen stock analysis report makes it easy to digest most publicly released information about Biogen and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biogen Stock analysis module also helps to analyze the Biogen price relationship with some important fundamental indicators such as market cap and management efficiency.

Biogen Stock Analysis Notes

About 87.0% of the company shares are held by institutions such as insurance companies. The book value of Biogen was currently reported as 70.93. The company recorded earning per share (EPS) of 19.29. Biogen Inc had not issued any dividends in recent years. The entity had 3:1 split on the 18th of January 2001. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people. For more info on Biogen Inc please contact George Scangos at 617 679 2000 or go to

Biogen Inc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biogen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biogen Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biogen Inc has very high historical volatility over the last 90 days
Over 87.0% of the company shares are held by institutions such as insurance companies
Latest headline from Macroaxis: Are Kibush investors switching to Biogen

Biogen Inc Upcoming and Recent Events

Earnings reports are used by Biogen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of February 2022
Next Financial Report28th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End2nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biogen SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biogen prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biogen investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biogen Inc specific information freely available to individual and institutional investors to make a timely investment decision.
20th of July 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
21st of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
3rd of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
7th of March 2022
Unclassified Corporate Event
10th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event
8th of February 2022
Unclassified Corporate Event
3rd of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Biogen Thematic Classifications

In addition to having Biogen stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Drug manufacturing and delivery

Biogen Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Primecap Management CoCommon Shares15.7 M3.2 B
Blackrock IncCommon Shares14.5 M2.9 B
Vanguard Group IncCommon Shares11.9 M2.4 B
State Street CorpCommon Shares6.9 M1.4 B
Wellington Management Group LlpCommon Shares6.3 M1.3 B
Geode Capital Management LlcCommon Shares3.2 M660.8 M
Jpmorgan Chase CoCommon SharesM402.8 M
Note, although Biogen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biogen Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 39.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biogen Profitablity

Biogen's profitability indicators refer to fundamental financial ratios that showcase Biogen's ability to generate income relative to its revenue or operating costs. If, let's say, Biogen is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biogen's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biogen's profitability requires more research than a typical breakdown of Biogen's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 19.36 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 32.92 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.33.

Management Efficiency

The entity has return on total asset (ROA) of 7.45 % which means that it generated profit of $7.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 13.65 %, meaning that it created $13.65 on every $100 dollars invested by stockholders. Biogen management efficiency ratios could be used to measure how well biogen inc manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 30th of September, Biogen shows the Risk Adjusted Performance of 0.1186, mean deviation of 2.07, and Downside Deviation of 2.24. Biogen Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Biogen Inc, which can be compared to its rivals. Please confirm Biogen Inc maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to decide if Biogen Inc is priced correctly, providing market reflects its regular price of 267.0 per share. Given that Biogen has jensen alpha of 0.7418, we suggest you to validate Biogen Inc's prevailing market performance to make sure the company can sustain itself at a future point.

Biogen Inc Price Movement Analysis

The output start index for this execution was thirty with a total number of output elements of thirty-one. The Moving Average is predictive technique used to analyze Biogen Inc price data points by creating a series of averages of different subsets of Biogen entire price series.

Biogen Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biogen Technical and Predictive Indicators

Biogen Forecast Models

Biogen time-series forecasting models is one of many Biogen's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Biogen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biogen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biogen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Biogen. By using and applying Biogen Stock analysis, traders can create a robust methodology for identifying Biogen entry and exit points for their positions.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people.

Current Biogen Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biogen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biogen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Biogen Inc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biogen Inc, talking to its executives and customers, or listening to Biogen conference calls.
Biogen Analyst Advice Details

Biogen Stock Analysis Indicators

Biogen Inc stock analysis indicators help investors evaluate how Biogen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biogen shares will generate the highest return on investment. By understating and applying Biogen stock analysis, traders can identify Biogen position entry and exit signals to maximize returns.
Quick Ratio1.36
Fifty Two Week Low187.16
Revenue Growth-6.70%
Average Daily Volume Last 10 Day3.12M
Shares Short Prior Month2.66M
Average Daily Volume In Three Month1.21M
Earnings Growth142.10%
Shares Percent Shares Out1.44%
Earnings Quarterly Growth135.90%
Gross Margins77.34%
Forward Price Earnings16.93
Short Percent Of Float1.63%
Float Shares144.68M
Fifty Two Week High290.76
Fifty Day Average210.61
Enterprise Value To Ebitda9.70
Two Hundred Day Average212.86
Enterprise Value To Revenue3.19
Continue to Trending Equities. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for analysis

When running Biogen Inc price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine Biogen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.